Elsevier

Urology

Volume 27, Issue 4, April 1986, Pages 291-301
Urology

Scientific article
Renal cell carcinoma: Survival and prognostic factors

https://doi.org/10.1016/0090-4295(86)90300-6Get rights and content

Abstract

Three hundred twenty-six patients treated at New York University from 1970 to 1982 were studied for survival in relationship to surgical stage, type of therapy, and pathologic characterization of the primary tumor. At the time of diagnosis 25.5 per cent of tumors were Stage I, 15 per cent Stage II, 28.5 per cent Stage III, and 31 per cent Stage IV. The retrospective study showed that patients with tumor confined within the capsule achieved the highest five- and ten-year survivals of 88 per cent and 66 per cent, respectively. Survivals decreased as tumor invaded perirenal fat (67% and 35 %) or regional lymph nodes (17 % and 5 %). Tumor invasion into the renal vein alone did not significantly change five-year survival (84 %) but lowered ten-year survival to 45 per cent. Patients with metastases at the time of nephrectomy did poorly regardless of site of metastases or kind of adjuvant therapy, except for those managed by surgical extirpation of the secondary lesion. Certain tumor characteristics were associated with a better prognosis, e.g., size below 5 cm in diameter, lack of invasion of collecting system, perirenal fat or regional lymph nodes, and predominance of clear or granular cells growing into a recognizable histologic pattern.

References (30)

Cited by (290)

  • The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013

    2019, Urologic Oncology: Seminars and Original Investigations
    Citation Excerpt :

    Although pN1 M0 RCC is associated with a poor prognosis, a subset of patients demonstrates long-term survival, with 10-year overall survival ranging from 5% to 39% [1–4]. Unfortunately, data regarding pN1 M0 RCC have been largely limited to small, institutional or multi-institutional series, and comprised cohorts treated predominantly prior to the introduction of targeted therapy [2–13]. Moreover, there is evidence for substantial heterogeneity in the clinical outcomes of patients with pN1 M0 RCC [2], highlighting a need for predictive tools to facilitate postoperative prognostication and risk-adapted management.

  • Kidney and Ureteral Carcinoma

    2015, Clinical Radiation Oncology
  • Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence

    2013, Urologic Oncology: Seminars and Original Investigations
    Citation Excerpt :

    A quarter of RCC patients present with locally advanced or metastatic RCC, and RCC is the 10th leading cause of cancer-related death in men [3]. Surgical resection of the affected kidney is the most reliable treatment modality for about 70% of locally advanced RCC [4,5], while 35%–65% of patients experience recurrence postoperatively [6]. Nephrectomy alone may not be sufficient as a strategy in high risk patients with locally advanced RCC.

View all citing articles on Scopus
View full text